[go: up one dir, main page]

PH12021500042A1 - Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection - Google Patents

Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection

Info

Publication number
PH12021500042A1
PH12021500042A1 PH1/2021/500042A PH12021500042A PH12021500042A1 PH 12021500042 A1 PH12021500042 A1 PH 12021500042A1 PH 12021500042 A PH12021500042 A PH 12021500042A PH 12021500042 A1 PH12021500042 A1 PH 12021500042A1
Authority
PH
Philippines
Prior art keywords
binding proteins
trispecific
cross
dual
variable domain
Prior art date
Application number
PH1/2021/500042A
Inventor
Mangaiarkarasi Asokan
Christian Beil
Jochen Beninga
Joerg Birkenfeld
Mark Connors
Richard A Koup
Young Do Kwon
Peter D Kwong
Qingbo Liu
Paolo Lusso
John R Mascola
Gary J Nabel
Amarendra Pegu
Ercole Rao
Ronnie Wei
Ling Xu
Zhi-Yong Yang
Original Assignee
Sanofi Sa
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Us Health filed Critical Sanofi Sa
Publication of PH12021500042A1 publication Critical patent/PH12021500042A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)

Abstract

Using the Cross-Over-Dual-Variable Domain (CODv) format, the present disclosure relates to compositions comprising trispecific and/ or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein a second pair of polypeptides possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.
PH1/2021/500042A 2019-04-09 2020-04-08 Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection PH12021500042A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831415P 2019-04-09 2019-04-09
EP19306312 2019-10-08
PCT/US2020/027313 WO2020210386A1 (en) 2019-04-09 2020-04-08 Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection

Publications (1)

Publication Number Publication Date
PH12021500042A1 true PH12021500042A1 (en) 2022-06-06

Family

ID=70471109

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/500042A PH12021500042A1 (en) 2019-04-09 2020-04-08 Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection

Country Status (15)

Country Link
EP (1) EP3953384A1 (en)
JP (1) JP7676316B2 (en)
KR (1) KR20210149796A (en)
CN (1) CN114096561A (en)
AU (1) AU2020273156A1 (en)
BR (1) BR112021020346A2 (en)
CA (1) CA3136147A1 (en)
CO (1) CO2021014988A2 (en)
IL (1) IL286932A (en)
MA (1) MA55609A (en)
MX (1) MX2021012384A (en)
PH (1) PH12021500042A1 (en)
SG (1) SG11202111011SA (en)
TW (1) TW202104274A (en)
WO (1) WO2020210386A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537827A (en) * 2021-09-29 2024-10-16 モードエックス セラピューティクス インコーポレイテッド Antigen-binding polypeptides, antigen-binding polypeptide complexes, and methods of their use in treating HIV
CN118317979A (en) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 Antigen binding polypeptides, antigen binding polypeptide complexes, and methods of use thereof
MX2024003807A (en) * 2021-09-29 2024-06-11 Modex Therapeutics Inc Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
RU2624046C2 (en) 2011-11-07 2017-06-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION
US9695230B2 (en) 2011-12-08 2017-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
WO2017011414A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
EP3365366B1 (en) * 2015-10-25 2021-07-14 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
JP7195929B2 (en) 2016-04-13 2022-12-26 サノフイ Trispecific and/or trivalent binding proteins
JP2019524687A (en) 2016-07-01 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Antibody drug conjugate and therapeutic method using the same
RU2020130795A (en) * 2018-02-21 2022-03-21 Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз NEUTRALIZING ANTIBODIES TO ENV HIV-1 AND THEIR USE
MX2021012386A (en) 2019-04-09 2022-01-18 Sanofi Sa Trispecific binding proteins, methods, and uses thereof.
IL300256A (en) * 2020-08-25 2023-03-01 Gilead Sciences Inc Multi-specific antigen binding molecules targeting hiv and methods of use

Also Published As

Publication number Publication date
EP3953384A1 (en) 2022-02-16
BR112021020346A2 (en) 2021-12-07
AU2020273156A1 (en) 2021-12-02
JP7676316B2 (en) 2025-05-14
MX2021012384A (en) 2022-02-21
JP2022526826A (en) 2022-05-26
TW202104274A (en) 2021-02-01
KR20210149796A (en) 2021-12-09
MA55609A (en) 2022-02-16
CO2021014988A2 (en) 2022-01-17
IL286932A (en) 2021-10-31
CN114096561A (en) 2022-02-25
WO2020210386A1 (en) 2020-10-15
CA3136147A1 (en) 2020-10-15
SG11202111011SA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
PH12018500873A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
PH12018502182A1 (en) Trispecific and/or trivalent binding proteins
MY208876A (en) Trispecific binding proteins, methods, and uses thereof
PH12021500042A1 (en) Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
EP4659757A3 (en) Multi-chain chimeric polypeptides and uses thereof
EP4442709A3 (en) Improved serum albumin binders
WO2020068752A8 (en) SIRPα BINDING PROTEINS AND METHODS OF USE THEREOF
MX2024008521A (en) Improved serum albumin binders.
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX2023004804A (en) Trispecific and/or trivalent binding proteins.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2024002182A (en) Tgf-beta-rii binding proteins.
WO2018057967A3 (en) Constructs targeting hiv peptide/mhc complexes and uses thereof
WO2021058711A3 (en) Antigen binding proteins
WO2021118156A3 (en) Switching binder, preparation method therefor, and pharmaceutical composition, assay kit, and antigen and antibody assay method, each using same
WO2020053742A3 (en) Anti-hla-hbv peptide antibodies
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
TN2018000345A1 (en) Trispecific and/or trivalent binding proteins
EA202191078A3 (en) TRISSPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION
AR118602A1 (en) TRIESPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR THE TREATMENT OF HIV INFECTION
WO2021081515A3 (en) Compositions and methods for the treatment of human immunodeficiency virus
WO2020247933A3 (en) Peptide inhibitors for the inhibition of hiv capsid